Credible Science

The primary purpose of this site is informational.  It is an opportunity for you to understand more about anti-oxidants and their properties to promote optimal health.  On these website pages, you can learn about us, see the relevant medical literature concerning our anti-oxidant under the Evidence-Based section and find specific answers readily under FAQ.

Our anti-oxidant is a nutraceutical, a food supplement. We fully disclose that our anti-oxidant has not been reviewed by the FDA.  In addition, we make it clear that we are not offering to make a diagnosis or proposing treatment for any disease.  Any and All health care issues are best determined by and under the care of a qualified health care provider.

Medical Literature:

The medical literature documents the health benefits of PCA. We have chosen the adjective “Broad Spectrum” because of the many applications documented in the published literature.

http://www.hindawi.com/journals/isrn/2014/952943/ 

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4337037/

http://www.ptfarm.pl/pub/File/Acta_Poloniae/2015/4/643.pdf

https://www.researchgate.net/publication/224808065_Protocatechuic_Acid_and_Human _Disease_Prevention_Biological_Activities_and_Molecular_Mechanisms [accessed Oct 22, 2016].

Patents

The following patents are in this portfolio as of May 24, 2022.  The specific claims of each may be viewed under the patent number at https://patft.uspto.gov/netahtml/PTO/srchnum.htm

September 11, 2012.  This patent showed that the dyes of plants (anthocyanins and anthocyanins) the precursor of the metabolite protocatechuic acid turned on the gene for growth hormone IGF-1 in human synovium.

November 8, 2016.  This patent secured the intra articular injection route not previously included in the granted patent claims for cyanidin-3-glucoside.

November 22, 2016.  This was the parent patent showing broad spectrum antibiotic properties and wound healing acceleration.  See the illustrations above.

March 27, 2018.This was a continuation of the parent application that adds 2,4,6 trihydroxybenzaldehyde to the broad-spectrum antibiotic, plus collagen proliferation (i.e. wrinkle treatment) and reduction in scar formation.

March 27, 2018.This was a continuation of the parent application that adds 2,4,6 trihydroxybenzaldehyde to the broad-spectrum antibiotic, plus collagen proliferation (i.e. wrinkle treatment) and reduction in scar formation.

May 15, 2018.  This patent secures that protocatechuic acid can only be manufactured and delivered to an end user by the owner of this patent.

 

June 5, 2018.  This patent was a continuation of 9,925,152 that now allowed for intra-articular injection.

July 26, 2018.  This patent included the metabolites of protocatechuic acid and 2,4,6 trihydroxybenzaldehyde for the destruction of biofilms of MRSA and Pseudomonas on metal, cloth and ceramic.

July 26, 2018.  This was an expansion of 10,004,705 applications.

July 10, 2018. This patent expanded the formulation for treatment of implants to include protocatechuic acid, 70% isopropyl alcohol, propylene glycol, and an essential oil.

July 31, 2018. This patent includes the chemical formulation of 10,016,380 for medical and surgical implants, dental implants and instrumentation.  The later for spaying or soaking in solution.

December 4, 2018. This patent secures the use of PCA to  coat a bandage or dressing at time or treatment and or a commercial preparation for as stated in claim #22 if a wound is a burn, skin break, bone break, muscle tear, puncture, surgical incision site, microdermabrasion site, skin graft site, a wound associated with diabetes, a bed sore, a pressure sore, skin defoliation, or a laceration, and wherein the protocatechuic acid becomes activated by contact with moisture from the wound.

April 23, 2019. An extension of prior claims that specifically cite PCA as an antibacterial for Propionibacterium acnes.  This for the treatment of skin acne.

May 21, 2019.   This patent extends the use of PCA to the food industry.

September 3, 2019. This is a non-surgical method of loosening biofilms from an implant via ultrasound and then treating without surgery.  The treatment would be repeated needle aspirations for infection status and then injection of protocatechuic acid crystals to destroy the biofilms attached to the implant.

October 1, 2019. This is an extension and further specification of the skin penetration formulation claims for pre-operative skin disinfection and facial acne with concentration above 10%.

September 5, 2020.  This is an extension that includes the disinfectant and sanitizer use emphasizing the residual anti-microbial protocatechuic acid coating the remains on the article and or person after the evaporation of the liquid vehicle.

 

March 30, 2021.  The treatment of COVID19 virus with protocatechuic acid.  This patent is for treating the patient; oral, intravenous, injection, etc.  

I claim:

1. A method of treating Covid-19 in a mammal comprising: administering to the mammal in need thereof a composition comprising protocatechuic acid. 
 
2. The method of claim 1, wherein the mammal is a human.

August 31, 2021.  Anti-microbials and the Methods and Use thereof. This patent is for mitigation of bacteria and virus (COVID 19) by coating of personal protective equipment; masks, gowns, hats, shoes, etc.

3/8/2022. Anti-microbials and the Methods and Use thereof.  This patent for the mitigation of SARS Co-2 virus on skin, protective equipment and hard surfaces.  

I claim: 
 
1. A method of interrupting the transmission of SARS CoV2 virus comprising: spraying, coating, fogging, and/or infusing a subject’s skin or personal protective equipment, room and/or facility, with a composition comprising protocatechuic acid, a liquid vehicle comprising an alcohol, and a stabilizer, the composition disinfecting SARS CoV2 virus on the subject’s skin or personal protective equipment, room and/or facility, upon contact; and forming a solid coating of protocathechuic acid on the subject’s skin or personal protective equipment, room and/or facility upon evaporation of the liquid vehicle, and disinfecting SARS CoV2 virus with the solid coating of protocatechuic acid for up to 24 hours.

May 24, 2022. Candida auris disinfectant. 

May 24, 2022. Compositions including combination of cannabinoid (CBS) and protocatechuic acid.

The recommended daily dose of a single 500 milligram pill of protocatechuic acid is below the amount that requires additional labeling by any state.

Inflammation is common to the unhealthy conditions in the human body.  In addition, pathological expression of bacteria are common to unhealthy conditions in the human body.

PCA is both anti-inflammatory and anti-microbial properties as established in the medical literature and the supporting evidence in the US patents granted to Dr. Johnson.  

We believe our pricing is fair, considering the purity of a single anti-oxidant, the independent laboratory confirmation of high concentration, low toxicity, and trace metals less than 9 parts per billion.  

If after being fully informed you decide to purchase, there will be no continuous monthly credit card billing.  If you benefit from your purchase, then you will make subsequent purchases. We have a single price that includes shipping and handling within the continental USA.  This avoids a surprise of an additional hidden high cost for shipping and handling.

We do not share your information with any other business or entity.